bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.49 USD
+0.02 (3.98%)
Updated Sep 23, 2024 03:59 PM ET
After-Market: $0.50 +0.01 (2.27%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BLUE 0.49 +0.02(3.98%)
Will BLUE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BLUE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BLUE
Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates
BLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
Other News for BLUE
Bluebird: Q1 Earnings Snapshot
bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q
Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
bluebird bio completes restated 10-K, delays 2024 Q2 10-Q
bluebird bio Announces September Investor Events